RxDoctor Payments Data

Matthew Ranalletta

Family · Putnam Valley, NYNPI 1629486188

Payments from drug & device makers

$1,963in general payments, 2019–2025

Across 112 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$386
  • Lilly USA, LLC$180
  • Johnson & Johnson$160
  • AstraZeneca$146
  • AbbVie$145
  • Pfizer$138
  • plus $808 from 17 others

What the payments were for

  • Food & beverage$1,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,963 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$129,569
Medicare patients
341
Services billed
1,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$59,693
EliquisApixaban28$40,055
MounjaroTirzepatide20$29,368
JardianceEmpagliflozin21$26,701
XareltoRivaroxaban20$23,590
JanumetSitagliptin Phos/Metformin Hcl14$16,820
LivaloPitavastatin Calcium15$9,793
Novolog FlexpenInsulin Aspart14$3,487
Duloxetine Hcl31$2,720
Pregabalin60$2,579
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,384
Rosuvastatin Calcium112$2,176
Levothyroxine Sodium126$2,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,010
SynthroidLevothyroxine Sodium37$1,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$386$59,69353 claims
PfizerEliquis$138$40,05528 claims
Lilly USA, LLCMounjaro$180$29,36820 claims
Boehringer IngelheimJardiance$90$26,70121 claims
Johnson & JohnsonXarelto$160$23,59020 claims
Kowa Pharmaceuticals America, Inc.Livalo$54$9,79315 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$2,031126 claims
AbbVieSynthroid$145$1,95937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Putnam Valley

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →